<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349801</url>
  </required_header>
  <id_info>
    <org_study_id>ECR-AMD-2017-13</org_study_id>
    <secondary_id>MACUSTAR</secondary_id>
    <nct_id>NCT03349801</nct_id>
  </id_info>
  <brief_title>Development of Novel Clinical Endpoints in Intermediate AMD</brief_title>
  <acronym>MACUSTAR</acronym>
  <official_title>Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frank G. Holz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association for Innovation and Biomedical Research on Light and Image</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City, University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Clinical Research Infrastructure Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>La Fondation Voir et Entendre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovative Medicines Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development of novel clinical endpoints for interventional clinical trials with a regulatory
      and patient access intention in patients with intermediate age-related macular degeneration
      (AMD) - MACUSTAR
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the MACUSTAR clinical study is to develop novel clinical endpoints for
      clinical trials with a regulatory and patient access intention in patients with intermediate
      age-related macular degeneration (iAMD). Additional objectives are to characterize the visual
      impairment in iAMD and its progression, as well as identify risk factors for progression to
      late stage AMD.

      Moreover, MACUSTAR aims to optimize and standardize most relevant existing and/or rapidly
      available clinical endpoints in:

        -  visual functional outcomes measures

        -  structural outcomes measures

        -  patient reported outcomes measures (PROMs)

      The study will be composed by two parts:

        -  a cross-sectional part to technically evaluate the functional and structural outcome
           measures to support a biomarker qualification by regulatory authorities and payers; and

        -  a longitudinal part to assess the prognostic power of changes in retinal sensitivity (as
           measured by microperimetry) for progression from iAMD to late AMD (nAMD and GA).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in best corrected visual acuity (BCVA) using an early treatment diabetic retinopathy study (ETDRS) chart</measure>
    <time_frame>3 years from baseline</time_frame>
    <description>standard parameter, tested for comparison (reference variable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in scotopic and mesopic microperimetry sensitivity</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in low luminance visual acuity (LLVA)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in vanishing optotypes visual acuity (VA)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in low luminance deficit (LLD)</measure>
    <time_frame>3 years from baseline</time_frame>
    <description>LLD = BCVA-LLVA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in absolute rod threshold of the dark adaptation test</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in rod intercept time of the dark adaptation test</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with progression in dark adaptation deficit beyond coefficient of repeatability structural</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in the cube root of drusen volume by spectral-domain optical coherence tomography (SD-OCT)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in retinal thickness by spectral-domain optical coherence tomography (SD-OCT)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Focal pigmentary changes captured by colour fundus photography (CFP)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of refractile deposits</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of intraretinal cystoid spaces</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of localized retinal pigment epithelium (RPE) hypertransmission</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of localized disruption of ellipsoid zone</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of localized subsidence of the outer plexiform layer and the inner nuclear layer</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of hyporeflective wedge-shaped bands</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of reticular drusen/subretinal drusenoid deposits and associated local changes as determined by multimodal imaging</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in localized fundus autofluorescence signal alterations</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with reduction in drusen volume</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with study eye that progressed to geogrphic atrophy (GA) and/or neovascular age-related macular degeneration (nAMD)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with conversions to late AMD detected with fluorescein angiography (FA) that could be detected with OCT-A (at equipped sites)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of quiescent choroidal neovascularisation (CNV) as assessed by optical coherence tomography angiography (OCT-A) (at equipped sites)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>OCT-A findings (at equipped sites)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in patient-reported low luminance visual functioning, as measured by the vision impairment in low luminance (VILL) questionnaire, including the domains of reading &amp; accessing information</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in patient-reported low luminance visual functioning, as measured by the VILL questionnaire, including the domains of Orientation &amp; mobility (incl. driving)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in patient-reported low luminance visual functioning, as measured by the VILL questionnaire, including the domains of safety</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in patient-reported low luminance visual functioning, as measured by the VILL questionnaire, including the domains of socio-emotional well-being</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in utility index from baseline as measure by the patient-reported outcome measure (PROM) utility index</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in patient-reported health status and utility using the EQ-5D-5L questionnaire (EuroQol Group)</measure>
    <time_frame>3 years from baseline</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Age Related Macular Degeneration (AMD)</condition>
  <arm_group>
    <arm_group_label>no AMD</arm_group_label>
    <description>No interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>early AMD</arm_group_label>
    <description>No interventions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intermediate AMD</arm_group_label>
    <description>No interventions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>late AMD</arm_group_label>
    <description>No interventions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>According to clinical practice.</description>
    <arm_group_label>no AMD</arm_group_label>
    <arm_group_label>early AMD</arm_group_label>
    <arm_group_label>intermediate AMD</arm_group_label>
    <arm_group_label>late AMD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples are collected in the study for two purposes: biobanking and genetic analysis.
      Detailed instructions on processing and storage of blood samples are provided in a specific
      manual that will be provided to the clinical sites. Blood samples are stored in a
      pseudonimysed form.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include subjects with no AMD or normal aging changes and subjects with AMD
        classified in accordance with the international Beckman Classification.

        A total of 750 subjects will be recruited:

          -  300 subjects will participate in the Cross-sectional part:

               -  50 with normal aging changes, no AMD

               -  50 with early AMD,

               -  50 with late AMD

               -  150 with iAMD

          -  650 subjects will participate in the longitudinal part:

               -  600 iAMD

               -  50 early AMD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion criteria (applicable to all groups)

          1. Male and female subjects.

          2. Aged 55 - 85 years at baseline.

          3. Able and willing to provide written informed consent and to comply with the study
             protocol visits and assessments.

        Intermediate AMD

          1. Study eye must have iAMD and,

          2. The fellow eye must have iAMD and/or, in addition, extrafoveal GA (no atrophy within
             the central ETDRS subfield), maximum total GA size is 1.25 mm2.

          3. ETDRS letter chart BCVA in the study eye not worse than 72 letters (approximately
             20/40 Snellen VA equivalent).

          4. All general inclusion criteria.

        Late AMD

          1. Subjects with bilateral GA, bilateral nAMD or nAMD in one eye and GA in the other.

          2. BCVA between 20/80 and 20/200 in study eye.

          3. All general inclusion criteria.

        Early AMD

          1. Subjects with medium drusen &gt; 63μm and ≤ 125μm and no AMD pigmentary abnormalities in
             both eyes and not signs of intermediate or late AMD.

          2. All general inclusion criteria.

        No AMD

          1. No signs of early, intermediate or late AMD in both eyes.

          2. All general inclusion criteria only.

        Exclusion Criteria:

        General Exclusion criteria (applicable to all groups)

          1. Media opacity or eye movement disorder (nystagmus) that interferes with retinal
             imaging data quality in the opinion of the investigator.

          2. Severe ptosis, extraocular motility restriction or head tremor preventing adequate
             fundus visualization in the opinion of the investigator.

          3. Any signs of nAMD or GA (does not apply to the late AMD group).

          4. Any concurrent intraocular condition in the study eye (e. g. glaucoma or cataract)
             that, in the opinion of the investigator would either require surgical intervention
             during the study to prevent or treat visual loss that might result from that condition
             or affect interpretation of study results.

          5. Severe non-proliferative diabetic retinopathy, or proliferative diabetic retinopathy.

          6. Any diabetic macular edema or macular disease

          7. Ocular disorders in the study eye (i. e., pre-retinal membrane) at the time of
             enrolment that may confound interpretation of study results and compromise visual
             acuity.

          8. Diagnosis of uncontrolled glaucoma with intraocular pressure of &gt;30 mmHg (despite
             current pharmacological or non-pharmacological treatment).

          9. Known systemic illness which in the opinion of the investigator will prevent from
             actively participating in the study.

         10. Concomitant treatment for AMD in either eye (concomitant use of vitamins/supplements
             is not excluded; does not apply to the late AMD group).

         11. Any periocular or intravitreal injections (IVT) in either eye (does not apply to the
             late AMD group).

         12. Participation in any other interventional trial.

         13. Obvious retinal changes due to causes other than AMD (e.g. evidenced by an existing
             diagnosis of monogenetic macular dystrophies, Stargardt disease, cone rod dystrophy,
             or toxic maculopathies).

         14. Any history of allergies to fluorescein.

        Intermediate AMD

          1. Any GA in the study eye

          2. Any extrafoveal GA larger than 1.25 mm2 in the fellow eye.

          3. All general exclusion criteria.

        Late AMD

        1. All general exclusion criteria only.

        Early AMD

          1. Intermediate or late AMD (following Beckman classification) in any eye.

          2. All general exclusion criteria.

        No AMD

          1. Early to late AMD (following Beckman classification) in any eye.

          2. All general exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Holz, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Lüning</last_name>
    <phone>+4922828715624</phone>
    <email>Anna.Luening@ukbonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Ferrao</last_name>
    <phone>+351239480131</phone>
    <email>macustar@aibili.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Righospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Larsen, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Creteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric Souied, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique Centre National d'Ophtalmologie des Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>José-Alain Sahel, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frank Holz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Claudia Dahlke, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hansjürgen Agostini, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Eye Hospital Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Armin Wolf, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Franziskus Hospital</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Daniel Pauleikhoff, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universtiy Hospital Tuebingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laura Kuhlwein, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Eye Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gabriele Lang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luigi Sacco Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giovanni Staurenghi, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesco Bandello, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>G.B.Bietti Eye Foundation</name>
      <address>
        <city>Rom</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Cristina Parravano, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Camiel Boon, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carel Hoyng, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Clinical Trials, AIBILI</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rufino Silva, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de São João, E.P.E.</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Angela Carneiro, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ruth Hogg, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emily Fletcher, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Adnan Tufail, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://macustar.eu</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Frank G. Holz</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>iAMD</keyword>
  <keyword>biomarker</keyword>
  <keyword>clinical endpoint</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

